[Skip to Content]
[Skip to Content Landing]
March 8, 1952


JAMA. 1952;148(10):843-844. doi:10.1001/jama.1952.62930100001014

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


The following case report constitutes one of a series in which varied malignant growths were treated with "krebiozen" to evaluate the effect of the drug. Since the drug allegedly had been standardized in vivo on the basis of beneficial influence on an untreated mammary carcinoma, it was felt that an untreated, relatively early, cervical malignant growth would offer a unique opportunity to observe any regression produced by the medicament alone.

REPORT OF A CASE  Mrs. A. J., a white woman, 56, was admitted to Mercy Hospital Institute of Radiation Therapy on June 5, 1951, complaining of vaginal discharge and bleeding since October, 1950. She had had an uneventful menopause in 1947 and had been in good health until the onset of her present symptoms. Her previous medical and surgical history was noncontributory. She had been delivered uneventfully of her only pregnancy 35 years previously.Her initial physical examination findings were

First Page Preview View Large
First page PDF preview
First page PDF preview